E. Ohman J or Asset Management AB Sells 400 Shares of Insulet Co. (NASDAQ:PODD)

E. Ohman J or Asset Management AB reduced its stake in Insulet Co. (NASDAQ:PODD) by 11.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,000 shares of the medical instruments supplier’s stock after selling 400 shares during the period. E. Ohman J or Asset Management AB’s holdings in Insulet were worth $783,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Baillie Gifford & Co. grew its stake in shares of Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares during the period. Geode Capital Management LLC grew its stake in shares of Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after purchasing an additional 22,850 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in shares of Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after acquiring an additional 3,113 shares in the last quarter.

Wall Street Analyst Weigh In

PODD has been the topic of several recent analyst reports. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Citigroup boosted their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Raymond James boosted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Canaccord Genuity Group boosted their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Morgan Stanley boosted their target price on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.13.

Insulet Stock Performance

PODD stock opened at $284.70 on Thursday. The business’s fifty day moving average is $269.53 and its 200-day moving average is $239.99. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market cap of $19.97 billion, a P/E ratio of 48.75, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $287.00.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the prior year, the business posted $0.71 EPS. Equities research analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This represents a 13.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.